Molecular Imaging of ABCB1/ABCG2 Inhibition at the Human Blood Brain Barrier using Elacridar and 11C-Erlotinib PET.

Abstract

Transporters such as ABCB1 and ABCG2 limit the exposure of several anti-cancer drugs to the brain, leading to suboptimal treatment in the central nervous system. The purpose of this study was to investigate the effects of the ABCB1/ABCG2 inhibitor elacridar on erlotinib brain uptake using 11C-erlotinib PET. Methods: Elacridar and cold erlotinib were… (More)
DOI: 10.2967/jnumed.117.195800

Topics

Cite this paper

@article{Verheijen2017MolecularIO, title={Molecular Imaging of ABCB1/ABCG2 Inhibition at the Human Blood Brain Barrier using Elacridar and 11C-Erlotinib PET.}, author={Remy B. Verheijen and Maqsood Yaqub and Emilia Sawicki and Olaf van Tellingen and Adriaan A. Lammertsma and Bastiaan Nuijen and Jan H. M. Schellens and Jos H. Beijnen and Alwin D. R. Huitema and N. Harry Hendrikse and Neeltje Steeghs}, journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine}, year={2017} }